# OrphanCure Full Pipeline Report: repodb_1f4ca25eed5d6b3c

- Drug: Everolimus
- Disease: Malignant tumor of colon
- Mode: full
- Status: completed
- Final assessment: Potential

This generated report is for research support only and is not medical advice.

## Structured Output

```json
{
  "sections": {
    "1_executive_summary": {
      "conclusion": "Potential",
      "confidence": "Medium",
      "summary": "Everolimus, an mTOR inhibitor, shows potential for repurposing in malignant colon neoplasm by inhibiting key pathways involved in cancer progression and inducing apoptosis. However, resistance mechanisms and limited single-agent efficacy in patients warrant further investigation, particularly in combination therapies.",
      "evidence_counts": {
        "total_papers": 11,
        "supporting": 0,
        "contradicting": 0,
        "inconclusive": 11
      },
      "common_targets_count": 0
    },
    "2_normalized_hypothesis": {
      "statement": "Repurpose EVEROLIMUS for malignant colon neoplasm",
      "drug": {
        "id": "CHEMBL1908360",
        "name": "EVEROLIMUS",
        "aliases": [
          "RAD001",
          "Certican",
          "Afinitor",
          "Zortress",
          "Votubia"
        ],
        "resolution_method": "auto"
      },
      "disease": {
        "id": "MONDO_0021063",
        "name": "malignant colon neoplasm",
        "aliases": [
          "colon cancer",
          "carcinoma of colon",
          "adenocarcinoma of colon",
          "cancer of the colon",
          "colorectal adenocarcinoma"
        ],
        "resolution_method": "auto"
      }
    },
    "3_mechanistic_rationale": {
      "total_mechanisms": 0,
      "mechanisms": []
    },
    "4_target_overlap_summary": {
      "total_overlapping": 0,
      "top_targets": []
    },
    "5_literature_evidence_summary": {
      "total_retrieved": 11,
      "polarity": {
        "supports": 0,
        "contradicts": 0,
        "inconclusive": 11
      },
      "support_ratio": "0 of 11 retrieved papers support the hypothesis",
      "queries_used": 10,
      "top_papers": [
        {
          "pmid": "38314724",
          "title": "Everolimus exerts anticancer effects through inhibiting the interaction of matrix metalloproteinase-7 with syndecan-2 in colon cancer cells.",
          "year": "2024",
          "relevance_score": 8.0,
          "polarity": "INCONCLUSIVE",
          "match_reasons": [
            "Recent"
          ]
        },
        {
          "pmid": "27351224",
          "title": "BRAFV600E-dependent Mcl-1 stabilization leads to everolimus resistance in colon cancer cells.",
          "year": "2016",
          "relevance_score": 5.5,
          "polarity": "INCONCLUSIVE",
          "match_reasons": []
        },
        {
          "pmid": "25867072",
          "title": "mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation.",
          "year": "2016",
          "relevance_score": 4.5,
          "polarity": "INCONCLUSIVE",
          "match_reasons": []
        },
        {
          "pmid": "25478811",
          "title": "mTOR and PDGF pathway blockade inhibits liver metastasis of colorectal cancer by modulating the tumor microenvironment.",
          "year": "2015",
          "relevance_score": 4.5,
          "polarity": "INCONCLUSIVE",
          "match_reasons": []
        },
        {
          "pmid": "31919616",
          "title": "Synchronous NET and colorectal cancer development: a case report.",
          "year": "2020",
          "relevance_score": 4.0,
          "polarity": "INCONCLUSIVE",
          "match_reasons": [
            "Case report limit"
          ]
        },
        {
          "pmid": "28759045",
          "title": "Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma.",
          "year": "2017",
          "relevance_score": 4.0,
          "polarity": "INCONCLUSIVE",
          "match_reasons": []
        },
        {
          "pmid": "34045438",
          "title": "Cyst(e)ine in nutrition formulation promotes colon cancer growth and chemoresistance by activating mTORC1 and scavenging ROS.",
          "year": "2021",
          "relevance_score": 3.5,
          "polarity": "INCONCLUSIVE",
          "match_reasons": []
        },
        {
          "pmid": "27462398",
          "title": "ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments.",
          "year": "2016",
          "relevance_score": 3.5,
          "polarity": "INCONCLUSIVE",
          "match_reasons": []
        },
        {
          "pmid": "25746901",
          "title": "Impact of the spheroid model complexity on drug response.",
          "year": "2015",
          "relevance_score": 2.0,
          "polarity": "INCONCLUSIVE",
          "match_reasons": []
        },
        {
          "pmid": "30448735",
          "title": "A Pilot Prospective Study of Refractory Solid Tumor Patients for NGS-Based Targeted Anticancer Therapy.",
          "year": "2019",
          "relevance_score": 2.0,
          "polarity": "INCONCLUSIVE",
          "match_reasons": []
        }
      ]
    },
    "6_contradictory_evidence": {
      "count": 2,
      "claims": [
        {
          "claim_id": "CTR-34aaf3",
          "statement": "BRAFV600E mutation confers resistance to everolimus in colon cancer cells by stabilizing Mcl-1.",
          "evidence_count": 1
        },
        {
          "claim_id": "CTR-7a3c2b",
          "statement": "Everolimus exhibits limited single-agent efficacy in patients with colon cancer.",
          "evidence_count": 1
        }
      ]
    },
    "7_confidence_assessment": {
      "overall": "Medium",
      "dimensions": {
        "mechanistic_strength": "High",
        "literature_strength": "Medium",
        "clinical_evidence": "Low"
      },
      "quality_scorecard": {
        "overall_score": 0.939,
        "decision": "finalize",
        "dimensions": {
          "completeness": {
            "score": 1.0,
            "reason": "5/5 sections present"
          },
          "evidence_support": {
            "score": 1.0,
            "reason": "7/7 claims have paper evidence"
          },
          "citation_validity": {
            "score": 1.0,
            "reason": "7 verified, 0 partial out of 7"
          },
          "mechanistic_specificity": {
            "score": 0.714,
            "reason": "5/7 claims reference targets"
          },
          "contradiction_handling": {
            "score": 0.8,
            "reason": "Contradictory evidence discussed"
          },
          "traceability": {
            "score": 1.0,
            "reason": "7/7 claims have provenance"
          },
          "output_structure": {
            "score": 1.0,
            "reason": "Executive summary + confidence assessment"
          },
          "actionability": {
            "score": 1.0,
            "reason": "3 next steps, 3 data gaps identified"
          }
        },
        "weak_dimensions": [],
        "rerun_targets": []
      }
    },
    "8_risk_flags_limitations": {
      "risk_flags": [
        "Limited single-agent efficacy.",
        "Emergence of drug resistance.",
        "Potential for drug interactions when combined with other therapies."
      ],
      "limitations": [
        "The provided literature primarily consists of preclinical studies and a case report.",
        "Clinical evidence for everolimus in malignant colon neoplasm is scarce.",
        "Resistance mechanisms are identified but not fully elucidated in the context of all colon cancer subtypes."
      ],
      "missing_data": [
        "Direct clinical trial data for everolimus in malignant colon neoplasm.",
        "Detailed information on optimal dosing and scheduling for everolimus in colon cancer.",
        "Comprehensive understanding of all resistance mechanisms beyond BRAFV600E."
      ]
    },
    "9_recommended_next_steps": {
      "clinical_next_steps": [
        "Investigate combination therapies of everolimus with agents targeting resistance mechanisms (e.g., BRAFV600E inhibitors).",
        "Conduct clinical trials to evaluate the efficacy and safety of everolimus in patients with malignant colon neoplasm, particularly in specific molecular subtypes.",
        "Explore the role of everolimus in managing cachexia in conjunction with anti-cancer treatments for colon cancer."
      ]
    },
    "10_claim_evidence_table": {
      "total_claims": 7,
      "claims": [
        {
          "claim_id": "CLM-fa5b42",
          "statement": "Everolimus exhibits anticancer effects in colon cancer cells by inhibiting the interaction of matrix metalloproteinase-7 with syndecan-2.",
          "confidence_numeric": 0.8,
          "confidence_label": "HIGH",
          "polarity": "INCONCLUSIVE",
          "verification_status": "VERIFIED",
          "targets": [
            "MMP7",
            "SDC2",
            "mTOR"
          ],
          "citation_count": 1,
          "risk_flags": []
        },
        {
          "claim_id": "CLM-fe75f4",
          "statement": "Everolimus induces apoptosis in colon cancer cells through the CHOP-dependent DR5 induction pathway.",
          "confidence_numeric": 0.8,
          "confidence_label": "HIGH",
          "polarity": "INCONCLUSIVE",
          "verification_status": "VERIFIED",
          "targets": [
            "mTOR",
            "CHOP",
            "DR5"
          ],
          "citation_count": 1,
          "risk_flags": []
        },
        {
          "claim_id": "CLM-325800",
          "statement": "Everolimus, in combination with other agents, can inhibit the growth and metastasis of human colon cancer.",
          "confidence_numeric": 0.7,
          "confidence_label": "HIGH",
          "polarity": "INCONCLUSIVE",
          "verification_status": "VERIFIED",
          "targets": [
            "mTOR",
            "PDGF-R"
          ],
          "citation_count": 1,
          "risk_flags": []
        },
        {
          "claim_id": "CLM-5b8d57",
          "statement": "Everolimus can block cystine-induced colon cancer cell proliferation by activating mTORC1.",
          "confidence_numeric": 0.8,
          "confidence_label": "HIGH",
          "polarity": "INCONCLUSIVE",
          "verification_status": "VERIFIED",
          "targets": [
            "mTORC1"
          ],
          "citation_count": 1,
          "risk_flags": []
        },
        {
          "claim_id": "CLM-caa13e",
          "statement": "Everolimus treatment can delay invasion of intestinal tumors, but its effect on blocking invasion is limited when administered later in tumor progression.",
          "confidence_numeric": 0.7,
          "confidence_label": "HIGH",
          "polarity": "INCONCLUSIVE",
          "verification_status": "VERIFIED",
          "targets": [
            "mTORC1"
          ],
          "citation_count": 1,
          "risk_flags": []
        },
        {
          "claim_id": "CTR-34aaf3",
          "statement": "BRAFV600E mutation confers resistance to everolimus in colon cancer cells by stabilizing Mcl-1.",
          "confidence_numeric": 0.5,
          "confidence_label": "MEDIUM",
          "polarity": "CONTRADICTS",
          "verification_status": "VERIFIED",
          "targets": [],
          "citation_count": 1,
          "risk_flags": []
        },
        {
          "claim_id": "CTR-7a3c2b",
          "statement": "Everolimus exhibits limited single-agent efficacy in patients with colon cancer.",
          "confidence_numeric": 0.5,
          "confidence_label": "MEDIUM",
          "polarity": "CONTRADICTS",
          "verification_status": "VERIFIED",
          "targets": [],
          "citation_count": 1,
          "risk_flags": []
        }
      ]
    },
    "11_provenance_appendix": {
      "total_entries": 7,
      "entries": [
        {
          "claim_id": "CLM-fa5b42",
          "source_agent": "SynthesisCriticAgent",
          "source_run": "5ebfa6eca338",
          "timestamp": "2026-06-03T14:26:26.179269+00:00",
          "paper_evidence": [
            {
              "pmid": "38314724",
              "snippet": "Among five candidates selected based on their structures and total energy values for interacting with the MMP-7 prodomain, the known mechanistic target of rapamycin kinase (mTOR) inhibitor, everolimus",
              "polarity": "SUPPORTS",
              "verification": "VERIFIED",
              "error": null
            }
          ],
          "mechanism_evidence": [],
          "queries_used_count": 10
        },
        {
          "claim_id": "CLM-fe75f4",
          "source_agent": "SynthesisCriticAgent",
          "source_run": "5ebfa6eca338",
          "timestamp": "2026-06-03T14:26:26.179269+00:00",
          "paper_evidence": [
            {
              "pmid": "25867072",
              "snippet": "We now show that apoptosis plays a key role in their anti-tumor activities in colon cancer cells and xenografts through the DR5, FADD and caspase-8 axis, and is strongly enhanced by tumor necrosis fac",
              "polarity": "SUPPORTS",
              "verification": "VERIFIED",
              "error": null
            }
          ],
          "mechanism_evidence": [],
          "queries_used_count": 10
        },
        {
          "claim_id": "CLM-325800",
          "source_agent": "SynthesisCriticAgent",
          "source_run": "5ebfa6eca338",
          "timestamp": "2026-06-03T14:26:26.179269+00:00",
          "paper_evidence": [
            {
              "pmid": "25478811",
              "snippet": "We investigated whether the mTOR inhibitor everolimus, alone or in combination with the PDGF-R tyrosine kinase inhibitor nilotinib, can inhibit growth and metastasis of human colon cancer.",
              "polarity": "SUPPORTS",
              "verification": "VERIFIED",
              "error": null
            }
          ],
          "mechanism_evidence": [],
          "queries_used_count": 10
        },
        {
          "claim_id": "CLM-5b8d57",
          "source_agent": "SynthesisCriticAgent",
          "source_run": "5ebfa6eca338",
          "timestamp": "2026-06-03T14:26:26.179269+00:00",
          "paper_evidence": [
            {
              "pmid": "34045438",
              "snippet": "mTORC1 inhibitors Rapamycin and Everolimus block cystine-induced cancer cell proliferation.",
              "polarity": "SUPPORTS",
              "verification": "VERIFIED",
              "error": null
            }
          ],
          "mechanism_evidence": [],
          "queries_used_count": 10
        },
        {
          "claim_id": "CLM-caa13e",
          "source_agent": "SynthesisCriticAgent",
          "source_run": "5ebfa6eca338",
          "timestamp": "2026-06-03T14:26:26.179269+00:00",
          "paper_evidence": [
            {
              "pmid": "28759045",
              "snippet": "In contrast, although everolimus treatment at earlier phase of tumor progression delayed invasion of the tumors, both inhibitors exhibited little effect on blocking invasion of the tumors when adminis",
              "polarity": "SUPPORTS",
              "verification": "VERIFIED",
              "error": null
            }
          ],
          "mechanism_evidence": [],
          "queries_used_count": 10
        },
        {
          "claim_id": "CTR-34aaf3",
          "source_agent": "SynthesisCriticAgent",
          "source_run": "5ebfa6eca338",
          "timestamp": "2026-06-03T14:26:26.179269+00:00",
          "paper_evidence": [
            {
              "pmid": "27351224",
              "snippet": "Using a panel of BRAF V600E and WT colorectal cancer cell lines and in vitro selected resistant culture, and xenograft models, we demonstrate here that BRAFV600E confers resistance to mTOR inhibitors.",
              "polarity": "CONTRADICTS",
              "verification": "VERIFIED",
              "error": null
            }
          ],
          "mechanism_evidence": [],
          "queries_used_count": 0
        },
        {
          "claim_id": "CTR-7a3c2b",
          "source_agent": "SynthesisCriticAgent",
          "source_run": "5ebfa6eca338",
          "timestamp": "2026-06-03T14:26:26.179269+00:00",
          "paper_evidence": [
            {
              "pmid": "27351224",
              "snippet": "However, mTOR inhibitors show limited single agent efficacy in patients.",
              "polarity": "CONTRADICTS",
              "verification": "VERIFIED",
              "error": null
            }
          ],
          "mechanism_evidence": [],
          "queries_used_count": 0
        }
      ]
    }
  },
  "metadata": {
    "run_id": "5ebfa6eca338",
    "created_at": "2026-06-03T14:26:05.310716+00:00",
    "drug": "EVEROLIMUS",
    "disease": "malignant colon neoplasm",
    "total_claims": 7,
    "quality_score": 0.9392857142857143,
    "reruns": 0
  }
}
```
